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ABSTRACT
The frequency of different types of mammary lesions and their relationship with histologic grade was 
investigated. One hundred and forty-six mammary lesions were classifi ed according to the World Health 
Organization (WHO) criteria. Selected lesions (51 malignant and 24 benign) were investigated to determine 
the immunohistochemical expression of estrogen receptor alpha (ERα), HER-2 and Ki-67 and their relationship 
with tumor factors. The most common breeds affected were cross breeds, poodles, cocker spaniels and German 
shepherds and the median age of tumor diagnosis was 10 years (range 4 - 15 years of age). Classifi cation 
of all canine mammary gland lesions revealed 110 (75.3%) malignant and 36 (24.7%) benign tumors. ERα 
was expressed by 9/24 (37.5%) benign and 9/51 (17.6%) malignant tumors. HER-2 protein was detected in 
5/51 (9.8%) malignant tumors but none in the 24 benign tumors. The Ki-67 index was higher in malignant 
(mean 29.5) than benign (mean 9.1) tumors (P<0.001) and signifi cantly higher in anaplastic carcinomas than 
tubulopapillary carcinomas (P<0.05).
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Introduction
Mammary tumors are among the most prevalent neoplasms in female dogs (LANA 
et al., 2007) and occur mostly in countries where dogs are not routinely spayed at an 
early age (SORENMO et al., 2000). The average age at fi rst detection is 10 - 11 years 
(GINN et al., 2007). According to the histologic diagnosis, between 41 and 53% of the 
mammary tumors that occur in bitches are considered to be malignant (LANA et al., 2007). 
Canine mammary tumors (CMT) are heterogeneous in their pathological features and 
clinical behavior (NIETO et al., 2000). Therefore, reliable prognostic factors are of great 
importance for estimating the individual risk of unfavorable clinical outcome. There are 
some recognized, well-accepted prognostic factors of malignant mammary tumors in 
dogs, such as tumor size, lymph node status, distant metastasis, histologic type, histologic 
malignancy grade, degree of nuclear differentiation and proliferative activity (BRATULIĆ 
et al., 1996; MISDORP et al., 1999; MISDORP, 2002; MARTIN de las MULAS et al., 2005), 
and also, the increasing availability of antibodies for immunohistochemical studies has 
allowed additional criteria to be evaluated (ZAIDAN DAGLI, 2008; MORRIS, 2010).
Estrogen receptors (ER) are expressed by more than 50% of canine mammary gland 
tumors (MARTIN de las MULAS et al., 2005; YANG et al., 2006; LANA et al., 2007), implying 
that reproductive hormones play an important role in the initiation and progression of 
mammary tumors, which is also supported by the protective effects of ovariectomy 
(SORENMO et al., 2000) and the sporadic occurrence of mammary dysplastic and neoplastic 
lesions in animals treated with progestagens (PEREZ ALENZA et al., 2000). Normal canine 
mammary glands, dysplasia and benign tumors differ from malignant tumors in expressing 
higher levels of ERα, and tumors that metastasize are frequently negative for ERα (NIETO 
et al., 2000; MILLANTA et al., 2005; MARTIN de las MULAS et al., 2005; YANG et al., 2006).
HER-2 (also known as neu, HER-2/neu and c-erbB-2) is a cell membrane receptor 
with an intracellular protein kinase domain and it belongs to a family of membrane-bound 
protein kinases that include an epidermal growth factor receptor (EGFR) (KILLEEN, 
2004). Overexpression of HER-2 is found in 20 - 30% of human breast carcinomas 
and such patients have shorter survival time and generally a poor prognosis (ROSS and 
FLETCHER, 1999; SAHIN, 2000; LESTER, 2010). This oncogene has also been explored as 
prognostic marker in CMT and studies showed that either HER-2 amplifi cation (AHERN 
et al., 1996) or HER-2 protein overexpression (RUNGSIPIPAT et al. 1999; MARTIN de las 
MULAS et al., 2003; HSU et al., 2009) were present in canine mammary tumors. One study 
using chromogenic in situ hybridization (CISH) indicated that gene amplifi cation was not 
present in canine mammary carcinomas (MARTIN de las MULAS et al., 2003), and another 
study demonstrated that dogs with HER-2 - overexpressing malignant mammary tumors 
tended to have a higher survival rate than those that expressed a normal level of HER-2 
(HSU et al., 2009).
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Neoplasms are characterized by an excessive and uncoordinated proliferation of 
cells (MISDORP, 2002). Studies on canine mammary tumors have revealed an association 
between proliferative activity and several clinical and pathological variables, such as 
histologic grade, nuclear pleomorphism, absence of hormonal receptors, metastasis and 
survival rate (PEREZ ALENZA et al., 1995; PENA et al., 1998; GERALDES et al., 2000). The 
Ki-67 nuclear antigen is one of the most commonly used immunohistochemical markers 
to evaluate tumor proliferative activity. It is expressed in all active phases of the cell 
cycle (G1, S, G2, M) but not in quiescent cells (G0) (GERDES et al., 1984). In canine 
mammary tumors, Ki-67 showed increased percentages of positive cellular staining with 
the increasing malignancy of the histologic type (GERALDES et al., 2000; MUTO et al., 
2000; YANG et al., 2006; MORRIS et al., 2009).
The present study was undertaken to determine the relative frequencies of different 
tumor types and the histologic malignancy grade (HMG) of mammary gland tumors in a 
population of female dogs in Croatia, and to investigate the expression of ERα, HER-2 
and Ki67 in dysplastic and neoplastic canine mammary tissue and their relationship with 
histologic grade.
Materials and methods
Histologic examination. Surgical specimens of canine mammary tissue submitted 
to the Department of veterinary pathology, University of Zagreb, from 2005 to 2007 
for diagnostic purposes were selected for review. The majority of specimens were 
from animals surgically treated at the Clinics of the Veterinary Faculty, and a smaller 
number of specimens were from private practices all around Croatia. Samples were fi xed 
in 10% neutral buffered formalin, and some samples were delivered already formalin 
fi xed. Samples were then embedded in paraffi n wax and 2 μm sections were stained with 
hematoxylin and eosin (H&E) for routine histopathological examination.
Classifi cation and grading of lesions. H&E stained sections of canine mammary 
tissue were classifi ed by two different pathologists, according to the diagnostic criteria 
proposed by the WHO (MISDORP et al., 1999). The histologic malignancy grade of the 
carcinomas was assessed according to MISDORP (2002), by examining tubule formation, 
intensity of nuclear staining and mitoses and nuclear pleomorphism. A score of 1 to 3 
was given for each feature, and to obtain the overall tumor grade, the scores for each 
factor are added together, giving a possible total of 3-9 pints. Tumor grade could then be 
allocated on the following basis: 3-5 points grade I (well differentiated tumors), 6-7 points 
grade II (moderately differentiated tumors) and 8-9 points grade III (poorly differentiated 
tumors).
Immunohistochemistry. Seventy-fi ve samples were selected (on the basis of the 
quality of tissue available) for immunohistochemical analysis, and assays were performed 
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on 2 μm sections of paraffi n-embedded tissue samples. The sections were dewaxed in 
xylene and rehydrated through a series of graded alcohol solutions. Antigen retrieval was 
carried out by microwave treatment with ethylenediaminetetraacetic acid (EDTA) buffer, 
pH 9 (DakoCytomation, Code S2367) for ERα 4x5 min, for HER-2 3x5 min, and for 
Ki-67 with citrate buffer pH 6 (DakoCytomation, Code S2031) for 20 min. Endogenous 
peroxidase activity was blocked by incubating the slides for 5 min at room temperature 
in Dako REALTM peroxidase blocking solution (DakoCytomation, Code S2023). Sections 
were incubated with primary antibodies for 30 min using the monoclonal mouse anti-
human ERα (DakoCytomation No. M7047) diluted 1:35, polyclonal rabbit anti-human 
c-erbB-2 (DakoCytomation No. A0485) diluted 1:350, and monoclonal mouse anti-
human Ki-67 (clone MIB-1, DakoCytomation No. M7240) diluted 1:75. This was 
followed by incubation for 30 min with a ready-to-use secondary antibody (Dako 
REALTM EnVisionTM/Horseradish Peroxidase, Rabbit/Mouse) and with the substrat Dako 
REALTM Diaminobenzidine + Chromogen for a further 10 min. Rinses were done with 
DakoCytomation Wash Buffer between each step. The sections were counterstained 
with hematoxylin and mounted. Sections from human benign breast tumor were used as 
positive control for ERα, from breast carcinoma as a positive control for HER-2 and from 
canine intestines as a positive control for Ki-67. The substitution of the primary antibody 
with phosphate buffered saline was used as negative control. 
Evaluation of immunohistochemical staining was executed semiquantitatively by 
examining the entire tumor present in the tissue section using an immunoperoxidase 
score. For ERα, the percentage of tumor cells with positive staining (proportion score, 
PS) was estimated and graded from 0 to 3. Zero points meant less than 5% staining, 1 
point represented 5-19%, 2 points 20-60%, and 3 points indicated more than 60% of the 
tumor nuclei showed positive staining. The staining intensity score (intensity score, IS) 
estimated the average staining intensity of positive tumor cells, and was scored as 0 = 
negative, 1 = faint, 2 = moderate staining, 3 = strong staining. The PS and IS were added 
to obtain a total score (TS) (range 0-6). ERα was considered positive when PS was ≥ 1 and 
TS ≥ 2 as previously described (MARTIN de las MULAS et al., 2005; YANG et al., 2006). For 
HER-2, immunostaining was scored according to the criteria specifi ed in the HercepTest 
as follows: 0 = no staining, +1 faint, incomplete membranous staining, +2 moderate, 
complete membranous staining, +3 strong membranous staining of at least 10% of tumor 
cells. Cases interpreted as 0 or +1 were considered negative, whereas scores +2 or +3 
were considered to indicate HER-2 overexpression. To determine Ki-67 scores, eight to 
10 representative tumor areas (mostly at the periphery of the tumor) were selected and 
at least 1000 cells were counted. The number of positive cells per 1000 examined was 
expressed as a percentage as previously described (PENA et al., 1998; MILLANTA et al., 
2002). 
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Statistical analysis. Data collected in the survey were statistically analyzed using 
the computer program STATISTICA (data analysis software system), StatSoft, Inc. 
(2006), Version 7.1. www.statsoft.com. To test the statistical signifi cance of differences 
among samples parametric and nonparametric tests of signifi cance were used. Statistical 
hypotheses were tested at the level of signifi cance of P=0.05, i.e. the difference between 
samples was considered to be signifi cant if P<0.05. The Kolmogorov-Smirnov test was 
used to check whether the data were normally distributed. Depending on the results of 
the Kolmogorov-Smirnov test, Single Factor analysis was performed using analysis of 
variance Kruskal-Wallis ANOVA. The Student-Newwman-Keuls (SNK) test was used as 
a complementary test to analyze the specifi c differences in Ki-67 expression among the 
HMG and in different tumor types.
Results
Dogs and tumors. The samples were from 146 dogs with a median age of 10 years 
(range: 4 to 15 years of age). The most common breeds affected were cross breeds (31), 
poodles (15), cocker spaniels (13), German shepherds (7), Yorkshire terriers (6), Pekingese 
(5) and four schnauzers, Irish setters and Siberian huskies. Other breeds were represented 
by three or fewer animals, and in 13 cases the breed was not specifi ed.
Histologic examination yielded 110 (75.3%) malignant tumors (35 complex 
carcinomas, 28 tubulopapillary carcinomas, 17 solid carcinomas, 10 anaplastic 
carcinomas, 4 squamous cell carcinomas, 2 spindle cell carcinomas, 4 sarcomas, 2 
carcinosarcomas, 8 carcinomas in benign tumors) and 36 (24.7%) benign tumors (14 
complex adenomas, 8 simple adenomas, 9 benign mixed tumors, 1 fi broadenoma and 4 
mammary hyperplasias).
The carcinomas studied included 50 (48.1%) well differentiated tumors (grade I), 35 
(33.7%) moderately differentiated tumors (grade II) and 19 (18.3%) poorly differentiated 
tumors (grade III) (Table 1).
Immunohistochemistry. Immunohistochemistry for ERα, HER-2 and Ki-67 was 
performed on 51 malignant and 24 benign canine mammary lesions (Table 1 and 3).
ERα immunostaining was localized in the nuclei of normal, benign and malignant 
epithelial cells (Fig. 1.). Positive immunolabeling for ERα was detected in 18/75 (24%) 
mammary lesions, including 9/51 (17.6%) malignant tumors and 9/24 (37.5%) benign 
lesions (Table 2). The ERα expression was not signifi cantly associated with tumor type 
or tumor grading.
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Table 1. Histological malignancy grade of 104 canine mammary carcinomas
Histological type HMG I HMG II HMG III Total
Complex carcinoma 24 7 4 35
Simple (tubulopapillary) carcinoma 16 11 1 28
Simple (solid) carcinoma 1 10 6 17
Simple (anaplastic) carcinoma - 4 6 10
Spindle cell carcinoma - 2 - 2
Squamous cell carcinoma 1 1 2 4
Carcinoma in benign tumor 8 - - 8
Total 50 35 19 104
Fig. 1. Mammary gland, dog; moderate nuclear immunostaining of ERα in majority of acinar 
epithelial cells in mammary hyperplasia. IHC, scale bar 100 μm.
Positive HER-2 immunoreactivity was localized in the cell membranes of neoplastic 
cells (Fig. 2.), and positive staining in most cases was distributed uniformly throughout the 
neoplastic cell population, although the immunostaining intensities of cells of individual 
tumors showed variations. HER-2 expression was detected in 5/51 (9.8%) malignant 
tumors and none of the benign lesions (Table 2). HER-2 status was not signifi cantly 
associated with histologic type or tumor grading. 
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Table 2. Expression of estrogen receptor α and HER-2 according to histologic classifi cation
Tumor ERα HER2
Malignant (51) 9 (17.6%) 5 (9.8%)
Complex carcinoma 2 1
Simple (tubulopapillary) carcinoma 3 2
Simple (solid) carcinoma 1 0
Simple (anaplastic) carcinoma 0 1
Carcinoma in benign tumor 2 1
Squamous cell carcinoma 1 0
Benign (24) 9 (37.5%) 0 -
Complex adenoma 2 0
Simple adenoma 1 0
Benign mixed tumor 2 0
Adenosis 4 0
Total 18 (24%) 5 (9.8%)
Fig. 2. Mammary gland, dog; moderate complete membranous staining (2+) of HER-2 in 
tubulopapillary carcinoma. IHC, scale bar 100 μm.
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Fig. 3. Mammary gland, dog, strong nuclear immunostaining of epithelial cells (Ki-67 index 60%) 
in squamous cell carcinoma. IHC, scale bar 100 μm.
Fig. 4. Immunohistochemical expression of Ki-67 above and below 20% immunopositivity 
in canine mammary lesions (HYP-hyperplasias; BM-benign mammary tumor; CA-complex 
adenoma; SA-simple adenoma; BT+ca-carcinoma in benign tumor; CC-complex carcinoma; 
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Table 3. Correlation between proliferative activity and some pathological variables in canine 
mammary tumors
Ki-67 index
n mean SEM P
Histology
Benign 22 9.1 7.0 P<0.001
Malignant 48 29.5 19.7
Histologic malignant grade P = 0.002
HMG 1 16 16.3* 12.2
HMG 2 18 33.4 20.9
HMG 3 14 39.6 17.9
Tumor type P = 0.011
Complex carcinoma 11 27.6 16.7
Tubulopapillary carcinoma 10 17.1 11.7
Solid carcinoma 11 31.9 16.7
Anaplastic carcinoma 7 46.6* 21.8
Squamous cell carcinoma 4 44.5 28.8
Carcinoma in benign tumor 5 17.7 14.2
*SNK test separated HMG I from HMG II and HMG III (P<0.05) and tubulopapillary from anaplastic 
carcinomas (P<0.05)
Ki-67 (MIB-1) immunostaining had a diffuse staining pattern that was confi ned to 
the nuclei but had variable intensity of staining both within and between samples (Fig.3). 
Of the 75 tumors, 70 had positive staining, and fi ve were discarded because they had no 
reaction to Ki-67. The majority of benign tumors had<20% immunopositive cells and 
the expression of Ki-67 was signifi cantly higher in malignant lesions (P<0.001) (Table 3, 
Fig. 4.). Among the malignant tumors, the SNK test separated HMG I from HMG II and 
HMG III (P<0,05) but there was no signifi cant difference in Ki-67 expression between 
HMG II and HMG III. In a comparison of the proliferative activity in different types 
of mammary carcinoma, anaplastic carcinomas had a signifi cantly higher Ki-67 index 
than tubulopapillary carcinomas (P<0.05), whereas there were no signifi cant differences 
among other types of carcinomas (Table 3). 
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Discussion
The frequencies of different types of mammary lesions and their distribution according 
to breed and age of female dogs in Croatia has not yet been established.
Considering the breed distribution, cross breeds, poodles and cocker spaniels were 
predominant, which is similar as in other studies (ZATLOUNKAL et al., 2005; HSU et al., 
2009; MORRIS et al., 2009). The age at diagnosis ranged from 4 to 15 years, with a median 
of 10 years. This interval of risk age is in agreement with other studies (NIETO et al., 2000; 
SARLI et al., 2002; YANG et al., 2006; MORRIS et al., 2009).
An interesting fi nding in this study was the high percentage of malignant mammary 
tumors (75.3%). According to literature data, 41% to 53% of mammary tumors that 
occur in bitches are considered malignant (MISDORP et al., 1999; LANA et al., 2007), and 
only a few investigations have shown a higher percentage of malignant tumors in the 
investigated period (YANG et al., 2006; MORRIS et al., 2009). In the present study data 
considering tumor size and OH (ovariohysterectomy) status were not included, which 
might be helpful in explaining the high percentage of malignant tumors. It could be 
supposed that late stage tumor removal possibly resulted in such a high percentage of 
malignant mammary tumors, as well as the high number of intact females and spaying 
at an older age, although it is well known that later spaying does not reduce the risk 
for malignant tumors (LANA et al., 2007). However, in spite of this high percentage of 
malignant mammary tumors, according to WHO classifi cation, the vast majority of 
malignant tumors were well differentiated adenocarcinomas, mostly complex and 
tubulopapillary, whereas special types of carcinomas and sarcomas were rare, which is 
similar as in other studies (RUNGSIPIPAT et al., 1999; MILLANTA et al., 2005; YANG et al., 
2006; THUROCZY et al., 2007; HSU et al., 2009; MORRIS et al., 2009). 
Another objective of this study was to investigate ERα, HER-2 and Ki-67 expression 
in selected dysplastic and neoplastic mammary lesions. Previous studies showed a 
decreasing percentage of ERα immunoreactivity with increasing malignancy (NIETO et 
al., 2000; MARTIN de las MULAS et al., 2005; YANG et al., 2006) and higher ERα expression 
in complex and mixed histologic subtypes of benign and malignant tumors (NIETO et 
al., 2000; MARTIN de las MULAS et al., 2005; MORRIS et al., 2009). Compared with other 
studies, our results showed a lower expression of ERα in benign (37.5%) and malignant 
(17.6%) canine mammary lesions. Some of the negative tumors did not contain additional 
normal or hyperplastic tissue and therefore it could not be determined if the loss of tissue 
antigenicity was due to fi xation or processing problems. Similar results were described 
by NIETO et al. (2000). 
In this study, HER-2 protein overexpression was observed in canine malignant 
mammary tumors, but not in benign lesions which is similar to the results of AHERN et al., 
(1996), MARTIN de las MULAS et al. (2003) and HSU et al. (2009). The percentage of HER-2 
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positive canine mammary carcinomas (9.8%) was lower than that reported in previous 
studies (19.1%, RUNGSIPIPAT et al., 1999; 17.6%, MARTIN de las MULAS et al., 2003; 21%, 
GAMA et al., 2008; 29.7%, HSU et al., 2009). HER-2 overexpression is related to a number 
of factors, including the sensitivity of the detection method, the level of gene expression 
or the stages of tumor samples (HSU et al., 2009). GOUVEA et al. (2006) compared the 
ability of different antibodies to detect HER-2 expression in human mammary carcinomas 
by IHC and found that results using monoclonal antibodies were more closely correlated 
with gene amplifi cation assessed by fl uorescent in situ hybridisation (FISH) than results 
using polyclonal antibodies, as was used in our study. 
Unlike ERα and HER-2, Ki-67 showed good immunoreactivity in almost all 
investigated samples (70/75). As expected from previous studies (PENA et al., 1998; 
GERALDES et al., 2000; De MATOS et al., 2006; THUROCZY et al., 2007; MORRIS et al., 
2009) Ki-67 showed increased percentages of positive nuclear staining with increasing 
histologic grade. We also identifi ed a signifi cantly higher Ki-67 index in anaplastic 
carcinomas compared to tubulopapillary carcinomas, in contrast with other studies, which 
did not fi nd any correlation between Ki-67 index and histologic type. Due to the low 
number of samples with ERα and HER-2 expression, it was not possible to investigate the 
correlation between Ki-67, ERα and HER expression. However, immunohistochemical 
staining with Ki-67 antibody represents a robust marker of cell proliferation in routinely 
processed canine mammary tumors, and the Ki-67 index was related to tumor grade and 
tumor types.
Nowadays, despite the vast array of immunohistochemical studies of ERα, HER-2, 
Ki-67 and many other oncogenes and tumor suppressor genes in the literature (DE MATOS 
et al., 2006; GAMA at al., 2008; ZAIDAN DAGLI, 2008; MORRIS et al., 2009; FERREIRA et al., 
2009), no such markers have been adopted for routine use by the veterinary profession 
(MORRIS, 2010). Also, many different scoring systems are applied for evaluation of 
immunohistochemical data (PENA et al., 1998; MARTIN de las MULAS et al., 2005; MILLANTA 
et al., 2005; MORRIS et al., 2009) which partly results in a wide range of results. However, 
even small immunohistochemical studies may contribute to fi nding prognostic markers, 
that will eventually improve diagnosis and treatment of canine mammary tumors.
_______
Acknowledgements
The work was supported by Ministry of Science, Education and Sport grant No. 053-0532264-2260.
References
AHERN, T. E., R. C. BIRD, A. E. CHURCH BIRD, L. G. WOLFE (1996): Expression of the 
oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines. Am. J. Vet. Res. 
57, 693-696. 
720 Vet. arhiv 81 (6), 709-722, 2011
A. Gudan Kurilj et al.: Estrogen receptor α, HER-2 and Ki-67 in canine neoplastic mammary lesions
BRATULIĆ, M., Ž. GRABAREVIĆ, B. ARTUKOVIĆ, D. CAPAK (1996): Number of nucleoli and 
nucleolar organizer regions per nucleus and nucleolus - prognostic value in canine mammary 
tumors. Vet. Pathol. 33, 527-532. 
DE MATOS, A. J. F., C. C. C. LOPES, A. M. FAUSTINO, J. G. V. CALVALHERA, M. S. A. 
DOS SANTOS, G. R. RUTTEMAN, M. D. R. M. GARTNER (2006): MIB-1 labeling indices 
according to clinico-pathological variables in canine mammary tumours: a multivariate study. 
Anticancer Res. 26, 1821-1826.
FERREIRA, E., A. C. BERTAGNOLLI, M. F. CAVALCANTI, F. C. SCHMITT, G. D. CASSALI 
(2009): The relationship between tumour size and expression of prognostic markers in benign 
and malignant canine mammary tumours. Vet. Comp. Oncol. 7, 230-235.
GAMA, A., A. ALVES, F. SCHMITT (2008): Identifi cation of molecular phenotypes in canine 
mammary carcinomas with clinical implications: application of the human classifi cation. 
Virchows Arch. 453, 123-132.
GERALDES, M., F. GÄRTNER, F. SCHMITT (2000): Immunohistochemical study of hormonal 
receptors and cell proliferation in normal canine mammary glands and spontaneous mammary 
tumors. Vet. Rec. 146, 403-406.
GERDES, J., H. LEMKE, H. BAISCH, H. H. WACKER, U. SCHWAB, H. STEIN (1984): Cell cycle 
analysis of a cell proliferation-associated human nuclear antigen defi ned by the monoclonal 
antibody Ki-67. J. Immunol. 133, 1710-1715. 
GINN, P. E., J. E. K. L. MANSELL, P. M. RAKICK (2007): Skin and appendages. In: Jubb, Kennedy 
and Palmer’s Pathology of Domestic Animals. (Maxie, E.G., Ed.). Elsevier, Saunders. Fifth 
edition. pp. 553-781.
GOUVEA, A. P., F. MILANEZI, S. J. OLSON, D. LEITAO, F. C. SCHMITT, H. GOBBI (2006): 
Selecting antibodies to detect HER2 overxpression by immunohistochemistry in invasive 
mammary carcinomas. Appl. Immunohistochem. Mol. Morphol. 14, 103-108.
HSU, W. L., H. M. HUANG, J. W. LIAO, M. L. WONG, S. C. CHANG (2009): Increased survival 
in dogs with malignant mammary tumours overexpressing HER-2 protein and detection of a 
silent single nucleotide polymorphism in the canine HER-2 gene. Vet. J. 180, 116-123.
KILLEEN, A. A. (2004): Principles of molecular pathology. Humana Press Inc. Totowa, New 
Jersey. pp. 185-209.
LANA, S. E., G. R. RUTTEMAN, S. J. WITHROW (2007): Tumors of the mammary gland. In: 
Small Animal Clinical Oncology. (Withrow, S. J., D. M. Vail, Eds.). Saunders, Elsevier. St. 
Louis, Missouri. pp. 619-636.
LESTER, S. (2010): The Breast. In: Robbins and Cotran Pathologic Basis of Disease. (Kumar, V., 
A. B. Abbas, N. Fausto, J. C. Aster, Eds.). 8th ed., Saunders, Elsevier. Philadelphia. pp. 1065-
1095. 
MARTIN de las MULAS, J., J. ORDÁS, Y. MILLÁN, V. FERNÁNDEZ-SORIA, S. 
RAMÓN Y CAJAL (2003): Oncogene HER-2 in canine mammary gland carcinomas: an 
immunohistochemical and chromagenic in situ hybridization study. Breast Cancer Res. Treat. 
80, 363-367. 
721Vet. arhiv 81 (6), 709-722, 2011
A. Gudan Kurilj et al.: Estrogen receptor α, HER-2 and Ki-67 in canine neoplastic mammary lesions
MARTIN de las MULAS, J., Y. MILLÁN, R. DIOS (2005): A prospective analysis of 
immunohistochemically determined estrogen receptor α and progesterone receptor expression 
and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. 
Vet. Pathol. 42, 200-212.
MILLANTA, F., G. LAZZERI, M. MAZZEI, I. VANNOZZI, A. POLI (2002): MIB-1 labeling 
index in feline dysplastic and neoplastic mammary lesions and its relationship with postsurgical 
prognosis. Vet. Pathol. 39, 120-126.
MILLANTA, F., M. CALANDRELLA, G. BARI, M. NICCOLINI, I. VANNAOZZI, A. POLI 
(2005): Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine 
and feline mammary tissues. Res. Vet. Sci. 79, 225-232.
MISDORP, W., R. W. ELSE, E. HELLMEN, T. P. LIPSCOMB (1999): WHO Histological 
Classifi cation of Tumors of Domestic Animals. Histological Classifi cation of Mammary 
Tumors of the Dog and the Cat. 2nd series, Volume VII. Washington DC: Armed Forces Institute 
of Pathology.
MISDORP, W. (2002): Tumors of the mammary gland. In: Tumors in Domestic Animals. (Meuten, 
D. J., Ed.). Iowa State Press. Ames. pp. 575-606.
MORRIS, J. S., C. NIXON, O. J. A. KING, I. M. MORGAN, A. W. PHILBEY (2009): Expression 
of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERα and p53. 
Vet. J. 179, 422-429.
MORRIS, J. S. (2010): Improving the diagnosis and treatment of canine mammary tumours: 
Immunohistochemical markers as a prognostic tools. Vet. J. 184, 3-4.
MUTO, T., S. WAKUI, H. TAKAHASHI, S. MAEKAWA, T. MASAOKA, S. USHIGOME, M. 
FURUSATO (2000): p53 gene mutations occuring in spontaneous benign and malignant 
mammary tumors of the dog. Vet. Pathol. 37, 248-253. 
NIETO, A., L. PENA, M. D. PEREZ-ALENZA, M. A. SANCHEZ, J. M. FLORES, M. CASTANO 
(2000): Immunohistologic detection of estrogen receptor alpha in canine mammary tumors: 
clinical and pathologic associations and prognostic signifi cance. Vet. Pathol. 37, 239-247.
PENA, L., A. I. NIETO, D. PEREZALENZA, P. CUESTA, M. CASTANO (1998): 
Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors - relationship 
to clinical and pathologic variables. J. Vet. Diagn. Invest. 3, 237-246.
PEREZ ALENZA, M. D., G. R. RUTTEMAN, N. J. KUIPERS-DIJKSHOORN, L. PENA, A. 
MONTOYA (1995): DNA fl ow cytometry of canine mammary tumours: the relationship of 
DNA ploidy and S-phase fraction to clinical and histological features. Res. Vet. Sci. 58, 238-
243.
PEREZ ALENZA, M. D., L. PENA, N. del CASTILLO, A. I. NIETO (2000): Factors infl uencing 
the incidence and prognosis of canine mammary tumours. J. Small Anim. Pract. 41, 287-291.
ROSS, J. S., J. A. FLETCHER (1999): The HER-2 neu oncogene: prognostic factor, predictive 
factor and target for therapy. Semin. Cancer Biol. 9, 125-138. 
RUNGSIPIPAT, A., S. TATEYAMA, R. YAMAGUCHI, K. UCHIDA, N. MIYOSHI, T. HAYASHI 
(1999): Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 
tumor suppressor protein in canine mammary tumors. J. Vet. Med. Sci. 61, 27-32.
722 Vet. arhiv 81 (6), 709-722, 2011
A. Gudan Kurilj et al.: Estrogen receptor α, HER-2 and Ki-67 in canine neoplastic mammary lesions
SAHIN, A. A. (2000): Biologic and clinical signifi cance of HER-2/neu (cerB-2) in breast cancer. 
Adv. Anat. Pathol. 7, 158-166. 
SARLI, G., R. PREZIOSI, C. BENAZZI, G. CASTELLANI, P. S. MARCATO (2002): Prognostic 
value of histologic stage and proliferative activity in canine malignant mammary tumors. J. 
Vet. Diagn. Invest. 14, 25-34.
SORENMO, K. U., F. S. SHOFER, M. H. GOLDSCHMIDT (2000): Effect of spaying and timing 
of spaying on survival of dogs with mammary carcinoma. J. Vet. Intern. Med. 14, 266-270.
THUROCZY, J., G. J. K. REISVAAG, E. PERGE, A. TIBOLD, J. SZILAGYI, L. BALOGH 
(2007): Immunohistochemical detection of progesterone and cellular proliferation in canine 
mammary tumours. J. Comp. Pathol. 137, 122-129. 
YANG, W. Y., C. H. LIU, C. J. CHANG, C. C. LEE, K. J. CHANG, C. T. LIN (2006): Proliferative 
activity, apoptosis and expression of oestrogen receptor and Bcl-2 oncoprotein in canine 
mammary tumours. J. Comp. Pathol. 134, 70-79.
ZAIDAN DAGLI, M. L. (2008): The search for suitable prognostic markers for canine mammary 
tumors: a promising outlook. Vet. J. 177, 3-5.
ZATLOUKAL, J., J. LORENZOVA, F. TICHY, A. NEČAS, H. KECOVA, P. KOHOUT (2005): 
Breed and age as a risk factors for canine mammary tumours. Acta Vet. Brno. 74, 103-109.
Received: 29 October 2010
Accepted: 17 March 2011
________________________________________________________________________________________
GUDAN KURILJ, A., M. HOHŠTETER, B. ARTUKOVIĆ, K. SEVERIN, 
I.-C. ŠOŠTARIĆ-ZUCKERMANN, A. BECK, S. SEIWERTH, R. SABOČANEC, 
Ž. GRABAREVIĆ: Histopatološko vrednovanje i imunohistokemijska analiza 
estrogenskih receptora α, HER-2 i Ki-67 u displastičnom i neoplastičnom tkivu 
mliječne žlijezde kuja. Vet. arhiv 81, 709-722, 2011.
SAŽETAK
U radu je prikazana učestalost različitih tipova lezija mliječne žlijezde u kuja te stupanj malignosti 
tumora. Sto četrdeset i šest lezija mliječne žlijezde je klasifi cirano prema kriterijima Svjetske zdravstvene 
organizacije. Odabrane lezije (51 maligna i 24 benigne) bile su podvrgnute imunohistokemijskoj analizi radi 
utvrđivanja ekspresije estrogenskih receptora alfa (ERα), HER-2 i Ki-67 te njihovoga značenja u odnosu na 
neke karakteristike tumora. Tumori mliječne žlijezde najčešće su bili utvrđeni u križane pasmine, pudla, koker 
španijela i njemačkih ovčara, a dijagnosticirani su prosječno u dobi od 10 godina (raspon od 4 do 15 godina). 
Klasifi kacija svih lezija mliječne žlijezde kuja pokazala je 75,3% malignih i 24,7% benignih tumora. Ekspresija 
ERα bila je utvrđena u 9/24 (37,5%) benignih i 9/51 (17,6%) malignih tumora. Ekspresija HER-2 proteina 
utvrđena je u 5/51 (9,8%) malignih tumora, a u benignih tumora nije bila utvrđena. Ki-67 indeks bio je veći u 
malignih (aritmetička sredina 29,5) nego u benignih (aritmetička sredina 9,1) tumora (P<0,001) te značajno veći 
u anaplastičnih nego u tubulopapilarnih karcinoma (P<0,05).
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